Evidence map›Paper›PMID 41676958›Full record

SynthesisEndocrinology, diabetes & metabolism2026

Comparing SGLT2i and Other Oral Antidiabetic Drugs as Dual Therapy Add-On to Metformin in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Yuhang Ma, Yi Lin, Xiaoying Ding, Yongde Peng

Abstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuhang MaDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-5931-5846
Yi LinDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiaoying DingDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0001-6290-8485
Yongde PengDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0001-9388-4922

Funding

AstraZeneca
6 · The paper itself

Abstract

aimsTo compare up-to-date efficacy and safety data of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) versus other metformin-containing oral dual-therapies (ODTs) in type 2 diabetes mellitus.

methodsWe updated a 2016 systematic literature review (SLR), searching MEDLINE, Embase, the Cochrane Database of Systematic Reviews, congress abstracts and SLR/meta-analysis (MA) bibliographies to identify randomised controlled trials. Two independent reviewers determined eligible studies, which were extracted and assessed using the Cochrane Risk of Bias tool. MA was conducted using random-effects pairwise models.

resultsWe included 36 publications (23 unique studies). Mean differences (MD) indicated comparable change in HbA

conclusionCompared with other ODTs, SGLT-2i plus metformin exhibited overall comparable efficacy and safety, with a lower risk of hypoglycaemia and greater weight reduction at Week 52.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsMetforminSodium-Glucose Transporter 2 InhibitorsAdministration, OralDrug Therapy, CombinationGlycated HemoglobinHumansGlycated HemoglobinHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 Inhibitorsdiabetes mellitushypoglycaemic agentsmeta‐analysismetforminsodium‐glucose transporter 2 inhibitorssystematic review

Identifiers

PMID41676958
PMCPMC12895371

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.